Biocon Biologics Expands Fujifilm Pact, Gets Exclusive Global Rights to Hulio

Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights to Hulio, its biosimilar version of adalimumab. This marks a major shift as the company now gains complete control over the product’s lifecycle.

What Changes Under the New Agreement?

Under the revised deal, Biocon Biologics will manage the entire product lifecycle, including manufacturing, development, and global commercialisation. Earlier, its role was largely limited to commercial rights, while FKB handled manufacturing and supply.

Manufacturing to Shift to Biocon Facilities

According to the exchange filing, commercial production will move to Biocon Biologics’ facilities after successful technology transfer and required regulatory approvals. This transition is expected to improve cost efficiency and operational flexibility.

Role of Fujifilm Kyowa Kirin Biologics

Despite transferring global rights, FKB will continue to support product development and will share some of the development costs. In return, Biocon Biologics will pay a technology licence fee and sales-based royalties to FKB for a defined period.

Strategic Rationale Behind the Move

Shreehas Tambe, CEO and MD of Biocon Biologics, said the expanded agreement gives the company end-to-end ownership of the biosimilar. He added that the move supports Biocon’s goal of improving access to high-quality biologics for patients with inflammatory diseases worldwide.

Background of Hulio

Biocon Biologics acquired the global commercial rights to Hulio in 2022 as part of its acquisition of Viatris’ biosimilars business. Viatris had earlier in-licensed the product from FKB, under which FKB retained manufacturing responsibilities.

Broader Biosimilars Strategy

Hulio is one of 3 immunology biosimilars in Biocon Biologics’ portfolio. The company has commercialised 10 biosimilars, serves over 6.3 million patients in 120+ countries, and has a pipeline of 20+ biosimilar assets across immunology, oncology and diabetology.

Read More, GRM Overseas Bonus Issue Record Date is Tomorrow, December 24! 

Biocon Biologics Share Price Update

Biocon share price (NSE: BIOCON) was trading at ₹401.05 on the NSE at around 10:50 am on December 23, up 0.44% for the day. The stock opened at ₹400.60 and moved between an intraday low of ₹399.60 and a high of ₹403.70. The company has a 52-week high of ₹424.95 and a 52-week low of ₹291, while it offers a dividend yield of 0.12%, with a quarterly dividend of ₹0.12 per share.

Conclusion

By securing full global rights to Hulio, Biocon Biologics has strengthened its control over a key biosimilar asset. The move is expected to boost efficiency, support long-term growth, and reinforce the company’s global biosimilars strategy.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.